ClinicalTrials.gg
CompletedNCT06637865Updated Sep 28, 2026

A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers

A Phase 1 interventional study of IMP761 and Placebo in Healthy, sponsored by Immutep S.A.S.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Immutep S.A.S. · Phase 1, Interventional, and Treatment

How we know

Updated Sep 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the safety and tolerability of single and multiple doses of IMP761 in healthy female and male volunteers aged 18-55 with no history of disease affecting the immune system or recent use of medication with effects on the immune system.

The main question it aims to answer is:

- if IMP761 is safe and tolerable as determined by assessing vital signs, emerging (serious) adverse events, electrocardiography, and clinical laboratory tests.

Researchers will compare IMP761 to a placebo (a look-alike substance that contains no drug) to see if single and multiple doses of IMP761 are safe and tolerable in healthy volunteers. Part B of the study also investigates the effect of IMP761 on the inhibition of the keyhole limpet haemocyanin (KLH) driven immune response compared with placebo.

Participants will:

  • receive IMP761 or a matching placebo intravenously once in single dose (part A and B) and three times in multiple dose (part C) during a 4 day in clinic stay with 4-8 following visits.
  • receive KLH challenge
  • be monitored for up to 103 days after the first dose.
Read the detailed description

This is a first in human, randomized, prospective, single centre, double blind, placebo-controlled study in healthy volunteers. It consists of three separate parts (Part A, B and C) with different study designs.

The main objective is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending dose (SAD) (Part A and B) and multiple ascending doses (MAD) (Part C) of IMP761 as assessed by:

  • Vital signs
  • Treatment-emergent (serious) adverse events ((S)AEs)
  • Electrocardiography.
  • Clinical laboratory tests
  • Laser speckle contrast imaging (LSCI)
  • Multispectral skin imaging

Part A: SAD study in healthy subjects (cohort 1, 5 subjects) Cohort 1: 5 subjects, single i.v. dose of IMP761 or placebo (3:2). The first 2 subjects will receive IMP761 or placebo (1:1) as sentinel dosing, while the following 3 subjects will receive IMP761 or placebo (2:1).

Part B: SAD study in healthy subjects, KLH challenge (cohort 2-8, 60 subjects) Cohort 2-3: 5 subjects, single i.v. dose of IMP761or placebo (4:1). Cohort 4-8: 10 subjects, single i.v. dose of IMP761 or placebo (8:2).

Part C: MAD study in healthy subjects (MAD cohort 1-2, 14 subjects) MAD Cohort 1-2: 7 subjects, multiple (three i.v. doses of IMP761 or placebo (5:2). Investigational Medicinal Product (IMP)/placebo administration every 28 days; dose selection to be based on observed pharmacodynamic effects in part B.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Immutep S.A.S. is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and willing and able to comply with the study protocol;
  2. Healthy men or women, 18 to 55 years of age (inclusive) at screening. The health status is verified by absence of evidence of any active or uncontrolled chronic disease following a detailed medical history, a complete physical examination including vital signs, laboratory measurements, and 12-lead (ECG);
  3. Female subjects agree to use effective for the duration of their participation in the study and until 186 days after End of Study (EOS).
  4. Male volunteers agree to use barrier protection when they engage in sexual relations with women of (WOCBP) or lactating women for the duration of their participation in the study and until 96 days after EOS.
  5. (BMI) between 18 and 32 kg/m2, inclusive, and with a minimum bodyweight of 50 kg;
  6. Fitzpatrick skin type I-III (cohorts 2-5 only);
  7. Has the ability to communicate well with the Investigator in Dutch language and willing to comply with the study restrictions.
  8. Has the intention to be reachable by mobile phone or e-mail during the whole study period.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator (following a detailed medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse rate, body temperature) and 12-lead (ECG)). Minor deviations from the normal range may be accepted, if judged by the Investigator to have no clinical relevance;
  2. abnormalities, as judged by the Investigator, in laboratory test results (including haematology panel, chemistry panel and urinalysis). In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility. A rescreen will be allowed based on judgement of the investigator;
  3. Positive immunodeficiency virus (HIV1, HIV2) antigen or antibody, surface antigen (HBsAg), Hepatitis B Virus antibody (HBV Ab), antibody (HCV Ab), (latent) Tuberculosis at screening;
  4. Any disease associated with immune system impairment, including immune mediated diseases, transplantation patients and any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug or multiple drug allergies (non-active hay fever is acceptable);
  5. Use of any medications (prescription or over-the-counter [OTC]), within 21 days prior to dosing with Medicinal Product (IMP), or less than 5 half-lives (whichever is longer). An exception is made for paracetamol (up to 4 g/day).
  6. Use of vitamin, mineral, herbal and dietary supplements within 7 days prior to study drug administration, which are deemed clinically significant by the investigator.
  7. Use of or immunomodulatory medication within 30 days prior to dosing with IMP or planned to use immunosuppressive or immunomodulatory medication during the course of the study.
  8. Any vaccination within 30 days prior to dosing with IMP or planned during the course of the study or within 90 days after the last dose of IMP.
  9. Use of antibiotic therapy within 90 days prior to dosing with IMP or planned to use during the course of the study.
  10. Subject is unable to abstain from travelling to areas with high endemic rates of infectious diseases from study entry until 90 days after the last dose of IMP
  11. Alcohol will not be allowed from at least 24 hours before screening and each scheduled visit. At other times during the course of the study no more than 2 units of alcohol per day will be allowed.
  12. If a woman, pregnant, or breast-feeding, or planning to become pregnant during the study.
  13. Have any current and/or recurrent clinically significant skin condition at the dermal challenge area (i.e. atopic dermatitis), including tattoos.
  14. Any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Single ascending dose IMP761 Part A

    Randomized in 3:2 (IMP761:placebo) Cohort 1: 5 subjects

    Drug: IMP761

  • Placebo comparator
    Single ascending dose Placebo Part A

    Randomized in 3:2 (IMP761:placebo) Cohort 1: 5 subjects

    Drug: Placebo

  • Experimental
    Single ascending dose IMP761 Part B KLH challenge

    Randomized in 4:1 (IMP761:placebo). KLH immunization followed by IMP761 on Day 1 and dermal rechallenge on day 2 (Cohorts 2-3) or on days 2, 9 and 23 (Cohorts 4-8) Cohort 2: 5 subjects; Cohort 3: 5 subjects; Cohort 4: 10 subjects; Cohort 5: 10 subjects; Cohort 6: 10 subjects; Cohort 7: 10 subjects; Cohort 8: 10 subjects

    Drug: IMP761 · Other: keyhole limpet haemocyanin (KLH)

  • Placebo comparator
    Single ascending dose Placebo Part B KLH challenge

    Randomized in 4:1 (IMP761:placebo). KLH immunization followed by placebo on Day 1 and dermal rechallenge on day 2 (Cohorts 2-3) or on days 2, 9 and 23 (Cohorts 4-8) Cohort 2: 5 subjects; Cohort 3: 5 subjects; Cohort 4: 10 subjects; Cohort 5: 10 subjects; Cohort 6: 10 subjects; Cohort 7: 10 subjects; Cohort 8: 10 subjects

    Drug: Placebo · Other: keyhole limpet haemocyanin (KLH)

  • Experimental
    Multiple ascending dose IMP761 Part C

    Randomized 5:2 (IMP761:placebo) every 28 days, 3 times. MAD Cohort 1: 7 subjects; MAD Cohort 2: 7 subjects

    Drug: IMP761

  • Placebo comparator
    Multiple dose placebo Part C

    Randomized 5:2 (IMP761:placebo) every 28 days, 3 times. MAD Cohort 1: 7 subjects; MAD Cohort 2: 7 subjects

    Drug: Placebo

Interventions

  • DrugIMP761

    intravenous

  • DrugPlacebo

    intravenous

  • Otherkeyhole limpet haemocyanin (KLH)

    intramuscular immunization and intradermal challenge

06

What researchers measure

Primary outcomes

  1. Occurrence of clinically relevant abnormalities in vital signs

    Time frame: From screening to the follow up visit after last treatment (up to 143 days)

  2. Frequency of adverse events (AEs)

    Time frame: From administration to the follow up visit after last treatment (up to 103 days)

  3. Duration of adverse events (AEs)

    Time frame: From administration to the follow up visit after last treatment (up to 103 days)

  4. Severity of adverse events (AEs)

    Time frame: From administration to the follow up visit after last treatment (up to 103 days)

  5. Occurrence of clinically relevant abnormalities in electrocardiography

    Time frame: From screening to the follow up visit after last treatment (up to 143 days)

  6. Occurrence of clinically relevant abnormalities in safety laboratory assessments

    Time frame: From screening to the follow up visit after last treatment (up to 143 days)

Secondary outcomes

  1. Pharmacokinetic (PK) parameter: Maximum Serum Concentration (Cmax) (Part B and C)

    Time frame: Up to 86 days

  2. PK parameter: Timepoint of Maximum Serum Concentration (tmax) (Part B and C)

    Time frame: Up to 86 days

  3. PK parameter: Minimum Serum concentration (Cmin) (Part B and C)

    Time frame: Up to 86 days

  4. PK parameter: Area Under the Curve (AUC) (Part B and C)

    Time frame: Up to 86 days

  5. PK parameter: systemic clearance (CL) (Part B and C)

    Time frame: Up to 86 days

  6. PK parameter: Apparent volume of distribution at steady state (Vss) (Part B and C)

    Time frame: Up to 86 days

  7. PK parameter: Apparent volume of distribution at terminal state (Vz) (Part B and C)

    Time frame: Up to 86 days

  8. PK parameter: elimination half-life (t1/2) (Part B and C)

    Time frame: Up to 86 days

  9. PK Parameter: Trough Concentration (Ctrough ) (Part C)

    Time frame: Up to 86 days

  10. PK Parameter: Peak to trough ratio (PTR) (Part C)

    Time frame: Up to 86 days

Other outcomes

  1. Pharmacodynamic (PD) parameter: Changes of erythema severity by multispectral skin imaging (Part B)

    Time frame: Day 2, 3, 9, 10, 23 and 24

  2. PD parameter: Changes of erythema shape by multispectral skin imaging (Part B)

    Time frame: Day 2, 3, 9, 10, 23 and 24

  3. PD parameter: Cutaneous microcirculation assessed using laser speckle contrast imaging (LSCI) (Part B)

    Time frame: Day 2, 3, 9, 10, 23 and 24

07

Study locations

1 site
  • CHDR
    Leiden, 2333, Netherlands
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Aug 2026, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Jul 17, 2024
Primary completionActual
Aug 27, 2026
CompletionActual
Aug 27, 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 28, 2026
Primary completion
Aug 31, 2026→Aug 27, 2026 (actual)
Sep 28, 2026
Study completion
Aug 31, 2026→Aug 27, 2026 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Recruiting→Completed
    Primary completion Aug 31, 2026→Aug 27, 2026 (now actual)
    Study completion Aug 31, 2026→Aug 27, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06637865
Lead sponsor
Immutep S.A.S.
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Jul 17, 2024
Primary completion
Aug 27, 2026
Completion
Aug 27, 2026
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion